


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously Presented) A compound of formula I



wherein

R^1 is H, OH, OA, CN, Hal, COR or CH_2R ,

R is by OH, OA, NH_2 , NHA or NA_2 ,

R^2 and R^3 are H or A,

A is an alkyl group with 1–10 atoms,

X is O or S,

Hal is F, Cl, Br or I


n is 2-6,

m is 1-4


p is 0, 1, 2, 3 or 4

or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.


- Claim 2.** (Previously Presented) A compound according to claim 1, wherein R¹ is F or CN.
- Claim 3.** (Previously Presented) A compound according to claim 1, wherein R³ is H.
- Claim 4.** (Canceled)
- Claim 5.** (Canceled)
- Claim 6.** (Previously Presented) A compound according to claim 1 of the formula I1 to I5:




I1




I2



I3



I4



I5

or a salt, solvate, enantiomer or racemate thereof.

Claim 7. (Previously Presented) A pharmaceutical composition comprising a formula I according to Claim 1 or physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Claims 8. – 14. (Canceled)

Claim 15. (Currently Amended) A method for the treatment of cerebral stroke, cerebral ischaemia, overexcitation, hyperactivity, attention disorder, deep-seated development disorder, mental retardation, depression, compulsive disorder, sleep disorders, sexual disorders, eating disorders, senile dementia or Alzheimer's dementia, schizophrenia, or for the control of psychotic-anxiety states, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.